Immuneering (IMRX) director Diana Hausman awarded 33,350 stock options at $4.12

Rhea-AI Filing Summary

Immuneering Corp director Diana Hausman received a grant of stock options covering 33,350 shares of Class A common stock. The options have an exercise price of $4.12 per share and were awarded as compensation, not purchased in the market.

The option grant vests in equal monthly installments over one year starting on July 11, 2026, and will be fully vested by June 11, 2027 or the date of the 2027 annual meeting of stockholders, whichever occurs first. After this grant, she holds options for 33,350 shares directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider HAUSMAN DIANA

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option	33,350	$0.00	--

Holdings After Transaction: Stock Option — 33,350 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 33,350 shares Exercise price: $4.12 per share Expiration date: June 11, 2036 +3 more

6 metrics

Option grant size 33,350 shares Stock options covering Class A common stock

Exercise price $4.12 per share Stock option strike price

Expiration date June 11, 2036 Option expiration

Vesting start July 11, 2026 Monthly vesting begins

Full vesting date June 11, 2027 Or 2027 annual meeting, whichever first

Options held after grant 33,350 options Total derivative holdings following transaction

Key Terms

Stock Option, Class A Common Stock, exercise price, vests and becomes exercisable, +1 more

5 terms

Stock Option financial

"security_title: "Stock Option""

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

Class A Common Stock financial

"underlying_security_title: "Class A Common Stock""

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

exercise price financial

"conversion_or_exercise_price: "4.1200""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vests and becomes exercisable financial

"The option vests and becomes exercisable in equal monthly installments"

annual meeting of stockholders financial

"on June 11, 2027, or the date of the 2027 annual meeting of stockholders"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HAUSMAN DIANA

(Last) (First) (Middle)

245 MAIN STREET

2ND FLOOR

(Street)

CAMBRIDGE MASSACHUSETTS 02142

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Immuneering Corp [ IMRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$4.12	06/11/2026		A		33,350		(1)	06/11/2036	Class A Common Stock	33,350	$0	33,350	D

Explanation of Responses:

1. The option vests and becomes exercisable in equal monthly installments over a one-year period commencing on July 11, 2026, and will be fully vested and exercisable on June 11, 2027, or the date of the 2027 annual meeting of stockholders, whichever comes first.

Remarks:

	/s/ Michael D. Bookman, Attorney-in-Fact for Diana F. Hausman	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Immuneering Corp (IMRX) director Diana Hausman report on this Form 4?

Diana Hausman reported receiving a stock option grant for 33,350 shares of Immuneering Class A common stock. The options were awarded as compensation and not bought on the open market, and are held directly in her name.

How many Immuneering (IMRX) shares are covered by Diana Hausman’s new options?

The option grant covers 33,350 shares of Immuneering Class A common stock. These are derivative securities that can be exercised into common shares at a fixed price once vesting conditions are met and the options become fully exercisable.

What is the exercise price of Diana Hausman’s Immuneering (IMRX) stock options?

The stock options have an exercise price of $4.12 per share. This means she can buy Immuneering Class A common stock at $4.12 per share once each portion of the grant vests and the options become exercisable over time.

When do Diana Hausman’s Immuneering (IMRX) options begin vesting and become fully vested?

The options begin vesting in equal monthly installments on July 11, 2026. They will be fully vested on June 11, 2027, or on the date of Immuneering’s 2027 annual meeting of stockholders, whichever takes place first according to the grant terms.

Is Diana Hausman buying or selling Immuneering (IMRX) stock in this Form 4?

She is not buying or selling stock on the market in this filing. Instead, she received a compensatory grant of stock options, giving her the right to purchase Immuneering shares later at $4.12 per share once the options vest.